Article: Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments.

UMEA, Sweden, August 6 /PRNewswire/ -- Omnio Healer AB, a pioneer company developing novel therapies for wound healing and anti-infection, today announced that it has entered into a partnership agreement with Eden Biodesign. Under the agreement Eden Biodesign will provide process development and cGMP production services relating to Omnio Healer's lead recombinant protein candidate.

Based on a novel therapeutic concept for wound healing and anti-infection, Omnio Healer is developing drug candidates with potent pro-inflammatory functions. The agreement with Eden Biodesign relates to the expression of proteins using mammalian cell culture for use against several ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!